CSF3 and Miyoshi myopathy: By comparison, in a contemporary cohort of demographically similar patients with MM prospectively enrolled in parallel to the GENESIS trial and mobilized with plerixafor + G-CSF, 50.0% of patients collected optimal numbers of CD34+ cells kg–1 in one apheresis (median, 5.47 × 106 CD34+ cells kg–1).